New treatment for childhood cancer demonstrate increased survival
Neuroblastoma only develops in babies and small children, usually before the age of two.
An international team of scientists, including researchers from Karolinska Institutet and Karolinska University Hospital, have conducted a clinical study on a new treatment for high-risk neuroblastoma.
According to the researchers, the results demonstrate that the new treatment both increases survival and reduces undesirable effects.
“This is a significant step forwards for these seriously ill children,” says consultant Per Kogner, professor of paediatric oncology at the Department of Women’s and Children’s Health, who led the Swedish arm of the study.